Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MDGL

Madrigal Pharmaceuticals Inc

Dec 01 • 04:00PM ET

213.12

Dollar change +9.82
Percentage change 4.83	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-19.24	Insider Own	27.89%	Shs Outstand	18.10M	Perf Week	8.98%
Market Cap	4.21B	Forward P/E	-	EPS next Y	-16.62	Insider Trans	5.38%	Shs Float	14.24M	Perf Month	56.14%
Income	-347.34M	PEG	-	EPS next Q	-5.20	Inst Own	87.94%	Short Float / Ratio	24.26% / 7.47	Perf Quarter	15.11%
Sales	0.00M	P/S	-	EPS this Y	-12.21%	Inst Trans	-1.85%	Short Interest	3.46M	Perf Half Y	-18.01%
Book/sh	1.20	P/B	177.15	EPS next Y	14.03%	ROA	-175.16%	Target Price	315.92	Perf Year	203.98%
Cash/sh	11.77	P/C	18.11	EPS next 5Y	0.00%	ROE	-2110.28%	52W Range	57.21 - 322.67	Perf YTD	-26.57%
Dividend	-	P/FCF	-	EPS past 5Y	-46.66%	ROI	-251.15%	52W High	-33.95%	Beta	-0.43
Dividend %	-	Quick Ratio	2.36	Sales past 5Y	0.00%	Gross Margin	-	52W Low	272.52%	ATR	10.28
Employees	92	Current Ratio	2.36	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	78.14	Volatility	5.31% 6.22%
Optionable	Yes	Debt/Eq	5.24	EPS Q/Q	-12.57%	Profit Margin	-	Rel Volume	0.89	Prev Close	203.30
Shortable	Yes	LT Debt/Eq	5.22	Earnings	Nov 06 BMO	Payout	-	Avg Volume	462.54K	Price	213.12
Recom	1.31	SMA20	26.66%	SMA50	41.56%	SMA200	-1.87%	Volume	412,017	Change	4.83%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135
May-05-20	Initiated	Chardan Capital Markets	Buy	$205
Jan-30-20	Initiated	Canaccord Genuity	Buy	$198
Jan-09-20	Upgrade	UBS	Neutral → Buy	$125 → $127
Nov-07-19	Reiterated	H.C. Wainwright	Buy	$225 → $215
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy	$128
Feb-28-19	Reiterated	H.C. Wainwright	Buy	$313 → $228
Feb-22-19	Initiated	SVB Leerink	Outperform	$165

Show Previous Ratings

Nov-27-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:00AM	Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-21-23 08:00AM	Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer (GlobeNewswire)
Nov-17-23 10:46AM	Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating (Investor's Business Daily)
03:03PM	Loading…
Nov-16-23 03:03PM	Baker Bros. Advisors LP Bolsters Position in Madrigal Pharmaceuticals Inc (GuruFocus.com)
Nov-15-23 04:45PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-23 10:56AM	The 3 Most Undervalued Biotech Stocks to Buy: November 2023 (InvestorPlace) +7.17%
Nov-13-23 04:40PM	Billionaire John Paulson's Messy Divorce and Top 5 Stock Picks (Insider Monkey) +5.16%
Nov-10-23 08:00AM	Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health (GlobeNewswire)
07:30AM	Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer (GlobeNewswire)
Nov-07-23 04:54AM	Madrigal Pharmaceuticals Inc (MDGL) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
Nov-06-23 08:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
06:29AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
04:05PM	Loading…
Nov-02-23 04:05PM	Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
Oct-17-23 09:53AM	2 Risky Stocks With Massive Potential (Motley Fool)
Oct-12-23 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:49AM	Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment? (Entrepreneur: Stocks)
Oct-02-23 11:51AM	Madrigal (MDGL) to Raise Capital Via Public Offering of $500M (Zacks)
Sep-29-23 12:41PM	5 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-28-23 10:30PM	Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering (GlobeNewswire)
04:01PM	Madrigal Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Sep-27-23 09:53AM	Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. (Motley Fool)
Sep-25-23 08:08PM	Goldman Sachs Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Sep-21-23 09:25AM	Weight-Loss Drugs Like Wegovy Are Bad News for These Stocks (Barrons.com)
09:25AM	Weight-Loss Drugs Like Ozempic Are Bad News for These Stocks (Barrons.com)
01:00AM	Weight-Loss Drugs Are Bad News for Companies That Treat Obesity Complications (Barrons.com)
Sep-20-23 07:00AM	1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street (Motley Fool)
04:30PM	Loading…
Sep-14-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.92%
Sep-13-23 04:10PM	Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line (Investor's Business Daily) +7.67%
09:10AM	Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis (GlobeNewswire)
Sep-11-23 07:00AM	Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer (GlobeNewswire) -5.90%
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-04-23 03:43PM	The 3 Best Biotech Stocks to Buy Now: September 2023 (InvestorPlace)
Aug-30-23 08:54AM	3 Biotech Stocks That Wall Street Analysts Cant Get Enough Of (InvestorPlace)
Aug-23-23 06:40AM	3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? (Motley Fool)
Aug-14-23 07:02PM	John Paulson's Q2 2023 13F Filing Update (GuruFocus.com)
Aug-08-23 08:50AM	Madrigal: Q2 Earnings Snapshot (AP Finance) -5.81%
08:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis (GlobeNewswire)
Jul-10-23 09:32AM	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why (Zacks)
09:29AM	Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand (Zacks)
Jul-09-23 09:07AM	Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Jul-07-23 08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
Jun-30-23 04:02PM	Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market (Investor's Business Daily)
09:34AM	UPDATE 1-Madrigal starts rolling submission for NASH drug application with US FDA (Reuters)
08:09AM	Madrigal Pharma begins submission of marketing application for NASH drug with US FDA (Reuters)
08:00AM	Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis (GlobeNewswire)
Jun-22-23 03:30AM	Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress (GlobeNewswire)
Jun-06-23 08:00AM	Madrigal Pharmaceuticals Supports International NASH Day on June 8 (GlobeNewswire)
Jun-01-23 08:00AM	Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences (GlobeNewswire)
May-24-23 01:17PM	Why Madrigal Pharmaceuticals Stock Is Marching Higher Today (Motley Fool)
11:59AM	Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days (Zacks)
May-22-23 12:02PM	Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation (Zacks)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
12:12PM	Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
May-16-23 03:42PM	Why These 3 Nasdaq Stocks Buckled Today (Motley Fool)
May-12-23 11:06AM	Intercept (ICPT) Gains 26.2% YTD: What's in Store? (Zacks)
May-11-23 10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
08:00AM	Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
May-09-23 01:54PM	Why Madrigal Pharmaceuticals Stock Is Slumping Today (Motley Fool)
08:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-20-23 02:06PM	Why Madrigal Pharmaceuticals Stock Gained 20% This Week (Motley Fool)
Apr-19-23 01:51PM	Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag (Zacks)
11:36AM	Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates (Zacks)
Apr-18-23 04:04PM	Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout (Investor's Business Daily) +12.77%
08:00AM	Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial (GlobeNewswire)
Mar-23-23 01:47PM	89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study (Zacks)
Mar-10-23 04:08PM	Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle (Investor's Business Daily) -5.39%
Mar-09-23 01:56PM	1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030 (Motley Fool)
Feb-23-23 10:30AM	2 Surging Healthcare Stocks That Are Still Worth Buying (Motley Fool) +5.22%
08:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results (GlobeNewswire)
Feb-13-23 04:55PM	Inside the NASH drug boom: New drugs for a silent liver disease that affects millions near FDA approval (MarketWatch)
Feb-08-23 08:00AM	Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire) -5.48%
Jan-30-23 05:40AM	Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit (Simply Wall St.)
Jan-20-23 09:53AM	Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA (Zacks)
Jan-13-23 11:41AM	Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why (Zacks)
Jan-06-23 08:00AM	Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis (GlobeNewswire)
Jan-04-23 11:44AM	Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal (Zacks)
Dec-26-22 05:21AM	This Stock That Tripled in 2022 Could Rocket Even Higher in 2023 (Motley Fool)
Dec-23-22 07:03AM	Why Madrigal Pharmaceuticals Was a Top Stock This Week (Motley Fool)
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks)
Dec-21-22 04:15PM	Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program (GlobeNewswire) +15.77%
Dec-20-22 08:14PM	Meet the Biotech Stock That Jumped Over 260% in One Day (TipRanks) +6.46%
03:00PM	Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says (Benzinga)
11:15AM	Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study (Zacks)
05:19AM	Estimating The Fair Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) (Simply Wall St.)
Dec-19-22 04:37PM	Madrigal Pharma Stock Soars 268% After Knocking NASH Study Out Of The Park (Investor's Business Daily) +268.07%
04:15PM	Madrigal Stock Triples After Liver Disease Drug Succeeds in Trial (Bloomberg)
04:08PM	Madrigal Pharmaceuticals Stock More Than Doubles on NASH Breakthrough (Barrons.com)
03:15PM	Madrigal's Successful Late-Stage Trial Draws Options Bulls (Schaeffer's Investment Research)
02:14PM	Surprising Fatty Liver Results Could Put Madrigal in Big Pharmas Sights (The Wall Street Journal)
01:33PM	Madrigal Pharmaceuticals Hits the NASH Jackpot. Its Stock Is Up 240%. (Barrons.com)
11:50AM	Why Madrigal Pharmaceuticals Stock Is Crushing It Today (Motley Fool)
11:00AM	Madrigal Pharmaceuticals Stock Jumps 250% on Test Results (The Wall Street Journal)
10:32AM	Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning (Motley Fool)
10:28AM	Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park (Investor's Business Daily)

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynch Brian Joseph	SVP and General Counsel	Nov 30	Option Exercise	73.75	3,000	221,250	18,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30	Sale	204.58	3,000	613,730	15,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29	Option Exercise	73.75	4,000	295,000	19,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29	Sale	199.19	4,000	796,750	15,001	Dec 01 04:30 PM
BAKER BROS. ADVISORS LP	Director	Nov 21	Buy	188.47	64,350	12,128,340	1,667,104	Nov 21 06:15 PM
BAKER BROS. ADVISORS LP	Director	Nov 20	Buy	185.74	20,709	3,846,575	1,607,668	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 17	Buy	174.70	46,370	8,100,704	1,588,541	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 15	Buy	161.97	15,199	2,461,721	1,545,775	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 14	Buy	154.00	37,660	5,799,653	1,500,227	Nov 15 05:12 PM
BAKER BROS. ADVISORS LP	Director	Nov 14	Buy	156.42	34,188	5,347,837	1,531,757	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 13	Buy	143.21	69,839	10,001,368	1,465,494	Nov 15 05:12 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 01	Option Exercise	87.92	5,000	439,600	10,667	Mar 02 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 01	Sale	274.42	5,000	1,372,081	5,667	Mar 02 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Feb 28	Option Exercise	87.92	5,000	439,600	10,667	Mar 02 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Feb 28	Sale	272.07	5,000	1,360,357	5,667	Mar 02 04:30 PM
Levy Richard S	Director	Jan 17	Option Exercise	103.02	22,489	2,316,844	31,589	Jan 19 07:57 PM
Levy Richard S	Director	Jan 17	Sale	293.15	22,489	6,592,686	9,100	Jan 19 07:57 PM
Lynch Brian Joseph	SVP and General Counsel	Jan 03	Option Exercise	91.79	13,000	1,193,270	13,000	Jan 06 09:08 AM
Lynch Brian Joseph	SVP and General Counsel	Jan 03	Sale	282.92	13,000	3,677,977	0	Jan 06 09:08 AM
Sukhija Remy	Chief Commercial Officer	Dec 23	Option Exercise	60.26	30,000	1,807,800	30,000	Dec 28 08:00 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 23	Option Exercise	91.79	7,000	642,530	7,000	Dec 28 08:00 PM
Sukhija Remy	Chief Commercial Officer	Dec 23	Sale	274.14	30,000	8,224,073	0	Dec 28 08:00 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 23	Sale	274.18	7,000	1,919,231	0	Dec 28 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDGL

Madrigal Pharmaceuticals Inc

Upgrade your FINVIZ experience